Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Abeona Therapeutics Inc. - Common Stock (NQ:ABEO)

5.785 -0.075 (-1.28%)
Streaming Delayed Price Updated: 10:24 AM EDT, May 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Abeona Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Abeona (ABEO) Q4 2025 Earnings Call Transcript ↗
Abeona (ABEO) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
Abeona Therapeutics (NASDAQ:ABEO) Reports First Commercial Revenue and Bolstered Balance Sheet in 2025 ↗
Via Chartmill
News headline image
Keep an eye on the top gainers and losers in Wednesday's session. ↗
Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Earnings Scheduled For November 12, 2025 ↗
 
Via Benzinga
News headline image
Here's Why Abeona Therapeutics Popped Higher Today ↗
This company is making excellent progress on its treatment for a very rare and serious skin disorder. 
Via The Motley Fool
News headline image
There are notable gap-ups and gap-downs in today's session. ↗
Let's have a look at the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Abeona Therapeutics (NASDAQ:ABEO) Stock Falls on Revenue Miss Despite Q3 EPS Beat ↗
Abeona Therapeutics beat Q3 EPS estimates but missed on revenue. The stock fell as investors focus on the delayed launch of its new gene therapy, ZEVASKYN. 
Via Chartmill
News headline image
What to Expect from Abeona Therapeutics's Earnings ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Abeona Posts Q2 Profit on Asset Sale ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
PDD Holdings Posts Weak Results, Joins EHang Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why E2open Shares Are Trading Higher By 25%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Which stocks have an unusual volume on Thursday? ↗
Let's have a look at what is happening on the US markets on Thursday. Below you can find the stocks with an unusual volume in today's session. 
Via Chartmill
News headline image
Wednesday's session: top gainers and losers ↗
Intrigued by the market activity one hour before the close of the markets on Wednesday? Uncover the key winners and losers of today's session in our insightful analysis. 
Via Chartmill
News headline image
Abeona Surges After FDA Clears First Gene Therapy For Severe Genetic Skin Disease ↗
Abeona's Zevaskyn secures timely FDA nod, priced at $3.1 million, with 2025 sales now forecast at $31.6 million and peak U.S. revenue projected at $600 million. 
Via Benzinga
News headline image
Abeona Stock Surges to 52-Week High: What's Behind The Move? ↗
Abeona shares are trading higher on Wednesday on possible continued strength after the FDA announced approval for its gene therapy. 
Via Benzinga
News headline image
Top stock movements in today's session. ↗
Looking for insights into the US markets in the middle of the day on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Abeona Therapeutics Wins FDA Approval For First-of-Its-Kind Gene Therapy ↗
FDA approves Zevaskyn as the first cell-based gene therapy for RDEB wounds after strong results in pivotal and long-term studies. 
Via Benzinga
News headline image
Abeona Therapeutics’ Gene Therapy Gets FDA Nod For Treating Rare Genetic Skin Disease ↗
ZEVASKYN is expected to be available beginning in the third quarter of 2025 through ZEVASKYN Qualified Treatment Centers, located across the U.S. with experience in cell and gene therapy. 
Via Stocktwits
News headline image
This Krystal Biotech Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗
 
Via Benzinga
News headline image
ABEO Stock Earnings: Abeona Therapeutics Beats EPS for Q2 2024 ↗
ABEO stock results show that Abeona Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
ABEO Stock Earnings: Abeona Therapeutics Misses EPS for Q1 2024 ↗
ABEO stock results show that Abeona Therapeutics missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Crude Oil Moves Higher; General Motors Earnings Top Views ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Why Nucor Shares Are Trading Lower? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
 
Via Benzinga
News headline image
Dow Jumps Over 200 Points; US Services PMI Falls In April ↗
 
Via Benzinga
Topics Stocks
News headline image
Why Is Affirm (AFRM) Stock Moving Today? ↗
Affirm stock is falling on Tuesday as AFRM investors react to BNPL loan service One being added to Walmart's retail stores. 
Via InvestorPlace
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.